XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation - Restricted Stock and Stock Options (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Weighted Average Grant Date Fair Value      
Compensation expense $ 11,431 $ 12,204  
Restricted Stock      
Changes in unvested restricted stock      
Unvested restricted shares, beginning of period (in shares) 628,732    
Issued (in shares) 815,627    
Vested (in shares) (154,834)    
Forfeited (in shares) (56,307)    
Unvested restricted shares, end of period(in shares) 1,233,218   628,732
Weighted Average Grant Date Fair Value      
Balance, beginning of period $ 41.28    
Issued (in dollars per share) 17.30    
Vested (in dollars per share) 52.88    
Forfeited (in dollars per share) 33.23    
Balance, ending of period $ 24.33   $ 41.28
Unrecognized stock-based compensation expense $ 19,100    
Period for recognition 2 years 10 months 24 days    
Performance based awards | Employees      
Changes in unvested restricted stock      
Issued (in shares) 259,367    
Stock options      
Weighted Average Grant Date Fair Value      
Unrecognized stock-based compensation expense $ 34,400    
Period for recognition 3 years 1 month 6 days    
Changes in unvested stock options      
Outstanding, beginning of period (in shares) 3,016,085    
Granted (in shares) 1,136,614    
Exercised (in shares) (12,573)    
Cancelled (in shares) (220,043)    
Outstanding, end of period (in shares) 3,920,083   3,016,085
Exercisable (in shares) 1,483,822    
Outstanding, beginning of period (in dollars per share) $ 34.24    
Granted (in dollars per share) 17.29    
Exercised (in dollars per share) 17.31    
Cancelled (in dollars per share) 30.30    
Outstanding, end of period (in dollars per share) 29.60   $ 34.24
Exercisable (in dollar per share) $ 29.34    
Remaining contractual life 7 years 10 months 24 days   7 years 6 months
Exercisable, remaining contractual life 6 years 6 months    
Aggregate intrinsic value $ 3,954,769   $ 5,052,469
Exercisable, aggregated intrinsic value $ 2,023,433